The United States market has experienced a notable upswing, climbing 3.9% over the last week and 33% over the past year, with earnings forecasted to grow by 16% annually. In this dynamic environment, identifying high growth tech stocks involves looking for companies that demonstrate strong innovation and adaptability to capitalize on these favorable conditions.
Name | Revenue Growth | Earnings Growth | Growth Rating |
---|---|---|---|
AsiaFIN Holdings | 51.75% | 58.17% | ★★★★★★ |
Invivyd | 47.87% | 67.72% | ★★★★★★ |
Sarepta Therapeutics | 23.89% | 42.65% | ★★★★★★ |
TG Therapeutics | 34.66% | 56.48% | ★★★★★★ |
Alkami Technology | 21.89% | 98.60% | ★★★★★★ |
Alnylam Pharmaceuticals | 22.45% | 70.66% | ★★★★★★ |
Blueprint Medicines | 25.26% | 68.92% | ★★★★★★ |
Travere Therapeutics | 31.19% | 72.58% | ★★★★★★ |
Seagen | 22.57% | 71.80% | ★★★★★★ |
ImmunoGen | 26.00% | 45.85% | ★★★★★★ |
Click here to see the full list of 240 stocks from our US High Growth Tech and AI Stocks screener.
Here's a peek at a few of the choices from the screener.
Simply Wall St Growth Rating: ★★★★★☆
Overview: Vericel Corporation is a commercial-stage biopharmaceutical company focused on the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America, with a market cap of $2.80 billion.
Operations: Vericel focuses on cellular therapies, generating revenue primarily from its biotechnology segment, which accounts for $226.84 million. The company's operations are centered in North America, targeting sports medicine and severe burn care markets.
Vericel's recent FDA approvals for MACI Arthro and pediatric NexoBrid signify strategic expansions in less invasive medical procedures and broader demographic reach, respectively. These innovations not only cater to a substantial segment of the $3 billion addressable market but also align with industry shifts towards specialized, patient-centric solutions. Financially, Vericel has demonstrated robust growth with a 21.3% increase in revenue year-over-year and is projecting continued expansion with revenue guidance set between $238 million to $242 million for 2024. This growth trajectory is underscored by an anticipated earnings increase of 51.6% annually over the next three years, reflecting both operational efficiency and market penetration.
Gain insights into Vericel's past trends and performance with our Past report.
Simply Wall St Growth Rating: ★★★★☆☆
Overview: AvePoint, Inc. offers a cloud-native data management software platform across North America, Europe, the Middle East, Africa, and Asia Pacific with a market cap of $2.94 billion.
Operations: AvePoint generates revenue primarily from its Software & Programming segment, which amounts to $315.92 million. The company's focus is on providing cloud-native data management solutions across multiple regions globally.
AvePoint's recent pivot towards AI-driven innovation, highlighted by the establishment of its AI Lab in collaboration with the Singapore Economic Development Board, underscores a strategic focus on leveraging artificial intelligence to enhance its SaaS offerings. This move is not only expected to spur significant research and development but also aligns with AvePoint's financial trajectory where earnings are forecasted to grow by an impressive 115.3% annually. Moreover, with a reported revenue increase of 17.5% year-over-year and a shift from a net loss to net income this quarter, AvePoint demonstrates robust potential in operational turnaround and market expansion.
Assess AvePoint's past performance with our detailed historical performance reports.
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Okta, Inc. operates as an identity partner both in the United States and internationally, with a market cap of approximately $13.33 billion.
Operations: As an identity partner, Okta generates revenue primarily from its Internet Software & Services segment, totaling $2.45 billion. The company's operations focus on providing identity solutions across various regions.
Okta's strategic partnerships, such as the recent collaboration with Persona for enhanced identity verification, underscore its commitment to securing digital identities amid increasing cyber threats. This initiative not only expands its service offerings but also strengthens its position in the cloud-based identity management sector. Additionally, Okta's financial performance has shown significant improvement with a jump in quarterly revenue from $556 million to $646 million and a swing to a net income of $29 million from a previous loss of $111 million. The company forecasts an encouraging revenue growth rate of 10.5% annually, outpacing the broader U.S. market projection of 8.9%. These developments reflect Okta's robust strategy in navigating the complexities of cybersecurity and identity management while enhancing shareholder value through focused R&D efforts which have been pivotal in transitioning from losses to profitability.
Gain insights into Okta's historical performance by reviewing our past performance report.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include NasdaqGM:VCEL NasdaqGS:AVPT and NasdaqGS:OKTA.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.